NEKTAR ANNOUNCES RECEIPT OF $17.6 MILLION PAYMENT FROM AFFYMAX, INC. UNDER AGREEMENT FOR NEKTAR ADVANCED PEGYLATION TECHNOLOGY

Nektar Therapeutics announced that it has received a $17.6 million payment under a previously undisclosed license agreement with Affymax, Inc. The cash payment under the Nektar-Affymax agreement was triggered by Affymax entering into a global agreement with Takeda, Inc. to develop and commercialize Affymax's lead product candidate, Hematide. Hematide utilizes Nektar Advanced PEGylation Technology and is in Phase IIb clinical trials for the treatment of anemia.
Genetic Engineering News